{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T20:18:50Z","timestamp":1760300330782},"reference-count":35,"publisher":"Japanese Circulation Society","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Circ Rep"],"published-print":{"date-parts":[[2020,1,10]]},"DOI":"10.1253\/circrep.cr-19-0080","type":"journal-article","created":{"date-parts":[[2019,12,13]],"date-time":"2019-12-13T17:03:50Z","timestamp":1576256630000},"page":"51-59","source":"Crossref","is-referenced-by-count":1,"title":["Clinical Considerations When Introducing Sodium-Glucose Co-Transporter 2 Inhibition in Patients With Heart Failure"],"prefix":"10.1253","volume":"2","author":[{"given":"Mayu","family":"Yazaki","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, Kitasato University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeru","family":"Nabeta","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Kitasato University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Inomata","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Kitasato University Kitasato Institute Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Maemura","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Kitasato University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takumi","family":"Ooki","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Kitasato University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teppei","family":"Fujita","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Kitasato University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichiro","family":"Iida","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Kitasato University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Ikeda","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Kitasato University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunsuke","family":"Ishii","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Kitasato University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Naruke","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Kitasato University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junya","family":"Ako","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Kitasato University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"330","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Emerging Risk Factors Collaboration, Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio E, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: A collaborative meta-analysis of 102 prospective studies. <i>Lancet<\/i> 2010; 376: 2215\u20132222.","DOI":"10.1016\/S0140-6736(10)60484-9"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Yasuda S, Miyamoto Y, Ogawa H. Current status of cardiovascular medicine in the aging society of Japan. <i>Circulation<\/i> 2018; 138: 965\u2013967.","DOI":"10.1161\/CIRCULATIONAHA.118.035858"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Nasir S, Aguilar D. Congestive heart failure and diabetes mellitus: Balancing glycemic control with heart failure improvement. <i>Am J Cardiol<\/i> 2012; 110: 50B\u201357B.","DOI":"10.1016\/j.amjcard.2012.08.031"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. <i>N Engl J Med<\/i> 2015; 373: 2117\u20132128.","DOI":"10.1056\/NEJMoa1504720"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. CANVAS Programme Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. <i>N Engl J Med<\/i> 2017; 377: 644\u2013657.","DOI":"10.1056\/NEJMoa1611925"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. <i>N Engl J Med<\/i> 2019; 380: 347\u2013357.","DOI":"10.1056\/NEJMoa1812389"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Fitchett D, Zinman B, Wanner C, Lachin JM, Hantel S, Salsali A, et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: Results of the EMPA-REG OUTCOME\u00ae trial. <i>Eur Heart J<\/i> 2016; 37: 1526\u20131534.","DOI":"10.1093\/eurheartj\/ehv728"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Davies MJ, D\u2019Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, et al. Management of hyperglycaemia in type 2 diabetes, 2018: A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <i>Diabetes Care<\/i> 2018; 41: 2669\u20132701.","DOI":"10.2337\/dci18-0033"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Das SR, Everett BM, Birtcher KK, Brown JM, Cefalu WT, Januzzi JL, et al. 2018 ACC expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes and atherosclerotic cardiovascular disease. <i>J Am Coll Cardiol<\/i> 2018; 72: 3200\u20133223.","DOI":"10.1016\/j.jacc.2018.09.020"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Patel PA, Heizer G, O\u2019Connor CM, Schulte PJ, Dickstein K, Ezekowitz JA, et al. Hypotension during hospitalization for acute heart failure is independently associated with 30-day mortality: Findings from ASCEND-HF. <i>Circ Heart Fail<\/i> 2014; 7: 918\u2013925.","DOI":"10.1161\/CIRCHEARTFAILURE.113.000872"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Metra M, Nodari S, Parrinello G, Bordonali T, Bugatti S, Danesi R, et al. Worsening renal function in patients hospitalised for acute heart failure: Clinical implications and prognostic significance. <i>Eur J Heart Fail<\/i> 2008; 10: 188\u2013195.","DOI":"10.1016\/j.ejheart.2008.01.011"},{"key":"12","unstructured":"12. Abassi ZA, Aronson D, Darawsha W, Azzam ZS, Boulos J. Treatment patterns of patients with acute heart failure who develop acute kidney injury. <i>ESC Heart Fail<\/i> 2018; 6: 45\u201352."},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Heise T, Jordan J, Wanner C, Heer M, Macha S, Mattheus M, et al. Pharmacodynamic effects of single and multiple doses of empagliflozin in patients with type 2 diabetes. <i>Clin Ther<\/i> 2016; 38: 2265\u20132276.","DOI":"10.1016\/j.clinthera.2016.09.001"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Tanaka H, Takano K, Iijima H, Kubo H, Maruyama N, Hashimoto T, et al. Factors affecting canagliflozin-induced transient urine volume increase in patients with type 2 diabetes mellitus. <i>Adv Ther<\/i> 2017; 34: 436\u2013451.","DOI":"10.1007\/s12325-016-0457-8"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Svensson MK, Afghahi H, Franzen S, Bj\u00f6rk S, Gudbj\u00f6rnsdottir S, Svensson AM, et al. Decreased systolic blood pressure is associated with increased risk of all-cause mortality in patients with type 2 diabetes and renal impairment: A nationwide longitudinal observational study of 27,732 patients based on the Swedish National Diabetes Regis. <i>Diabetes Vasc Dis Res<\/i> 2017; 14: 226\u2013235.","DOI":"10.1177\/1479164116683637"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: An update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. <i>Eur Heart J Cardiovasc Imaging<\/i> 2015; 16: 233\u2013271.","DOI":"10.1093\/ehjci\/jev014"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. D\u00edaz A, Z\u00f3calo Y, Cabrera-Fischer E, Bia D. Reference intervals and percentile curve for left ventricular outflow tract (LVOT), velocity time integral (VTI), and LVOT-VTI-derived hemodynamic parameters in healthy children and adolescents: Analysis of echocardiographic methods association and agreement. <i>Echocardiography<\/i> 2018; 35: 2014\u20132034.","DOI":"10.1111\/echo.14176"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Melenovsky V, Andersen MJ, Andress K, Reddy YN, Borlaug BA. Lung congestion in chronic heart failure: Haemodynamic, clinical, and prognostic implications. <i>Eur J Heart Fail<\/i> 2015; 17: 1161\u20131171.","DOI":"10.1002\/ejhf.417"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Ling HZ, Flint J, Damgaard M, Bonfils PK, Cheng AS, Aggarwal S, et al. Calculated plasma volume status and prognosis in chronic heart failure. <i>Eur J Heart Fail<\/i> 2015; 17: 35\u201343.","DOI":"10.1002\/ejhf.193"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Baker WL, Smyth LR, Riche DM, Bourret EM, Chamberlin KW, White WB. Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: A systematic review and meta-analysis. <i>J Am Soc Hypertens<\/i> 2014; 8: 262\u2013275.","DOI":"10.1016\/j.jash.2014.01.007"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Bailey CJ. Renal glucose reabsorption inhibitors to treat diabetes. <i>Trends Pharmacol Sci<\/i> 2011; 32: 63\u201371.","DOI":"10.1016\/j.tips.2010.11.011"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Chilton R, Tikkanen I, Cannon CP, Crowe S, Woerle HJ, Broedl UC, et al. Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes. <i>Diabetes Obes Metab<\/i> 2015; 17: 1180\u20131193.","DOI":"10.1111\/dom.12572"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. List JF, Whaley JM. Glucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humans. <i>Kidney Int<\/i> 2011; 79: S20\u2013S27.","DOI":"10.1038\/ki.2010.512"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Rahman A, Fujisawa Y, Nakano D, Hitomi H, Nishiyama A. Effect of a selective SGLT2 inhibitor, luseogliflozin, on circadian rhythm of sympathetic nervous function and locomotor activities in metabolic syndrome rats. <i>Clin Exp Pharmacol Physiol<\/i> 2017; 44: 522\u2013525.","DOI":"10.1111\/1440-1681.12725"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Chiba Y, Yamada T, Tsukita S, Takahashi K, Munakata Y, Shirai Y, et al. Dapagliflozin, a sodium-glucose co-transporter 2 inhibitor, acutely reduces energy expenditure in BAT via neural signals in mice. <i>PLoS One<\/i> 2016; 11: e0150756.","DOI":"10.1371\/journal.pone.0150756"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Van Bommel EJ, Muskiet MH, Tonneijck L, Kramer MH, Nieuwdorp M, van Raalte DH. SGLT2 inhibition in the diabetic kidney: From mechanisms to clinical outcome. <i>Clin J Am Soc Nephrol<\/i> 2017; 12: 700\u2013710.","DOI":"10.2215\/CJN.06080616"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. <i>N Engl J Med<\/i> 2001; 345: 851\u2013860.","DOI":"10.1056\/NEJMoa011303"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Vardeny O, Vaduganathan M. Practical guide to prescribing sodium-glucose cotransporter 2 inhibitors for cardiologists. <i>JACC Heart Fail<\/i> 2019; 7: 169\u2013172.","DOI":"10.1016\/j.jchf.2018.11.013"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Anders H, Davis JM, Thurau K. Nephron protection in diabetic kidney disease. <i>N Engl J Med<\/i> 2016; 375: 2096\u20132098.","DOI":"10.1056\/NEJMcibr1608564"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. <i>N Engl J Med<\/i> 2019; 377: 644\u2013657.","DOI":"10.1056\/NEJMoa1811744"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Convertino VA. Gender differences in autonomic functions associated with blood pressure regulation. <i>Am J Physiol<\/i> 1998; 275: R1909\u2013R1920.","DOI":"10.1152\/ajpregu.1998.275.6.R1909"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Schlotman TE, Akers KS, Nessen SC, Convertino VA. Differentiating compensatory mechanisms associated to low tolerance to central hypovolemia in females. <i>Am J Physiol Circ Physiol<\/i> 2019; 316: H609\u2013H616.","DOI":"10.1152\/ajpheart.00420.2018"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Forman DE, Butler J, Wang Y, Abraham WT, O\u2019Connor CM, Gottlieb SS, et al. Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. <i>J Am Coll Cardiol<\/i> 2004; 43: 61\u201367.","DOI":"10.1016\/j.jacc.2003.07.031"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Cowie MR, Komajda M, Murray-Thomas T, Underwood J, Ticho B. Prevalence and impact of worsening renal function in patients hospitalized with decompensated heart failure: Results of the Prospective Outcomes Study in Heart Failure (POSH). <i>Eur Heart J<\/i> 2006; 27: 1216\u20131222.","DOI":"10.1093\/eurheartj\/ehi859"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Nieminen MS, B\u00f6hm M, Cowie MR, Drexler H, Filippatos GS, Jondeau G, et al. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: The Task Force on Acute Heart Failure of the European Society of Cardiology. <i>Eur Heart J<\/i> 2005; 26: 384\u2013416.","DOI":"10.1093\/eurheartj\/ehi044"}],"container-title":["Circulation Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circrep\/2\/1\/2_CR-19-0080\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,10]],"date-time":"2020-01-10T22:19:16Z","timestamp":1578694756000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circrep\/2\/1\/2_CR-19-0080\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,10]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1253\/circrep.cr-19-0080","relation":{},"ISSN":["2434-0790"],"issn-type":[{"value":"2434-0790","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,10]]}}}